**Core Concept**
Autoimmune hemolytic anemia (AIHA) is a condition where the immune system produces antibodies against the patient's own red blood cells, leading to their premature destruction. In severe cases, splenectomy (surgical removal of the spleen) is often considered to reduce the destruction of red blood cells. However, alternatives to splenectomy are being explored to minimize the risks associated with surgery.

**Why the Correct Answer is Right**
Rituximab, a monoclonal antibody against CD20-positive B cells, has been shown to be effective in reducing the production of autoantibodies against red blood cells in patients with AIHA. By depleting B cells, rituximab decreases the production of autoantibodies, thereby reducing the destruction of red blood cells. This mechanism of action makes rituximab an attractive alternative to splenectomy in patients with severe AIHA.

**Why Each Wrong Option is Incorrect**
**Option A:** Corticosteroids are often used as first-line treatment for AIHA, but they are not an alternative to splenectomy, as they do not address the underlying immune response.

**Option B:** Danazol, an androgenic medication, has been used off-label for AIHA, but its effectiveness is variable and it is not a suitable alternative to splenectomy.

**Option C:** Plasma exchange therapy involves removing antibodies from the blood to reduce their levels, but it is typically used as a short-term measure to rapidly reduce antibody levels, rather than as a long-term alternative to splenectomy.

**Clinical Pearl / High-Yield Fact**
Rituximab is also used in the treatment of other autoimmune diseases, such as rheumatoid arthritis and lupus, due to its ability to deplete B cells and reduce autoantibody production.

**Correct Answer:** C. Rituximab